Vivint Pharma, an injectables pharmaceutical company, announced its plans to establish a state-of-the-art injectables manufacturing facility in Genome Valley, Hyderabad. The estimated investment for this project is INR 400 Crore.
Moreover, Vivint Pharma has chosen to build its first manufacturing plant on an anticipated 5.5 Acres of land parcel. The facility will focus on developing and producing high-quality injectable drugs for oncology and critical care. Additionally, it will cater to both domestic and international markets. The new facility would create employment for about 1,000 people.
Also Read: Industrial Construction Trends in India’s South and Central Zones: FY 2023-24 – A Zone-Wise Analysis – Part 4 of 4
The company also has an R&D center in Genome Valley, having invested about INR 70 Crore in this facility. Through these strategic investments, Vivint Pharma demonstrates its commitment to innovation and excellence in pharmaceutical manufacturing.
Biltrax Construction Data is tracking 32,000+ projects on their technology platform for their clients.
Get exclusive access to upcoming projects in India with actionable insights. Furthermore, gain a competitive advantage for your products in the Indian Construction Market.
Visit www.biltrax.com or email us at contact@biltrax.com to become a subscriber and generate leads.
Disclaimer: The information herein is based upon information obtained in good faith from sources believed to be reliable. All such information and opinions can be subject to change. Furthermore, The image featured in this article is for representation purposes only. It does not in any way represent the project. If you wish to remove or edit the article, please email editor@biltrax.com.
0Discover more from Biltrax Media, A Biltrax Group venture
Subscribe to get the latest posts sent to your email.
